Equillium Financials

EQ Stock  USD 0.75  0.03  3.85%   
Equillium is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At this time, Equillium's Non Currrent Assets Other are relatively stable compared to the past year. As of 03/17/2025, Long Term Debt is likely to grow to about 7 M, while Property Plant And Equipment Net is likely to drop slightly above 682.7 K. Key indicators impacting Equillium's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio1.962.06
Notably Down
Slightly volatile
Investors should never underestimate Equillium's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Equillium's cash flow, debt, and profitability to make informed and accurate decisions about investing in Equillium.

Net Income

(12.6 Million)

  
Understanding current and past Equillium Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Equillium's financial statements are interrelated, with each one affecting the others. For example, an increase in Equillium's assets may result in an increase in income on the income statement.

Equillium Stock Summary

Equillium competes with Lyra Therapeutics, Hookipa Pharma, Jasper Therapeutics, SAB Biotherapeutics, and Anebulo Pharmaceuticals. Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California. Equillium operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 45 people.
Foreign Associate
  Canada
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS29446K1060
CUSIP29446K106
LocationCalifornia; U.S.A
Business Address2223 Avenida De
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.equilliumbio.com
Phone858 240 1200
CurrencyUSD - US Dollar

Equillium Key Financial Ratios

Equillium Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets85.4M85.4M78.4M50.5M58.1M67.5M
Other Current Liab2.8M5.9M10.7M6.7M7.7M4.6M
Other Liab200K127K54K10.4M11.9M12.5M
Net Tangible Assets41.8M69.9M66.5M31.9M36.7M50.0M
Net Debt(15.7M)(40.4M)(48.9M)(22.4M)(20.2M)(21.2M)
Retained Earnings(70.9M)(110.0M)(172.4M)(185.7M)(167.2M)(158.8M)
Accounts Payable2.8M1.2M4.0M4.7M5.4M5.7M
Cash24.0M50.4M59.1M23.2M26.7M32.3M
Long Term Debt9.7M8.3M8.8M3.2M3.7M7.0M
Capital Surpluse80.4M82.9M141.1M176.6M203.1M105.8M
Other Current Assets3.3M3.0M4.5M2.2M2.5M2.6M
Total Liab15.6M18.9M46.5M28.0M32.2M21.1M
Net Invested Capital79.8M8.8M40.9M22.6M20.3M31.3M
Total Current Assets85.4M83.8M77.2M49.3M56.8M66.9M
Net Working Capital77.9M74.8M44.7M21.8M25.0M23.8M
Common Stock789.01K2K3K3.5K1.9K
Other Assets(254K)153K3.4M1.01.151.09

Equillium Key Income Statement Accounts

The reason investors look at the income statement is to determine what Equillium's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
202020212022202320242025 (projected)
Interest Income476K57K420K2.0M2.3M2.4M
Interest Expense1.1M1.1M1.1M491K441.9K748.9K
Gross Profit(45K)(72K)15.6M36.0M41.4M43.4M
Operating Income(29.5M)(37.8M)(62.1M)(14.5M)(13.1M)(13.7M)
Ebit(29.5M)(37.8M)(61.4M)(12.3M)(11.0M)(11.6M)
Research Development19.4M26.4M37.5M37.0M42.6M22.7M
Cost Of Revenue45K72K118K126K144.9K152.1K
Income Before Tax(29.8M)(39.1M)(62.4M)(12.8M)(11.5M)(12.1M)
Net Income(29.8M)(39.0M)(107.7M)(13.3M)(12.0M)(12.6M)
Income Tax Expense(45K)(72K)45.3M580K667K633.7K
Net Interest Income(623K)(1.0M)(633K)1.3M1.4M1.5M
Ebitda(29.5M)(37.7M)(61.3M)(12.1M)(10.9M)(11.5M)

Equillium Key Cash Accounts

202020212022202320242025 (projected)
Investments(18.6M)27.5M18.7M7.8M8.9M9.4M
Change In Cash10.8M26.4M8.7M(35.9M)(32.3M)(30.7M)
Depreciation45K72K118K126K144.9K152.1K
Capital Expenditures202K57K279K50K57.5K109.9K
Net Income(29.8M)(39.1M)(62.4M)(13.3M)(12.0M)(12.6M)
End Period Cash Flow24.0M50.4M59.1M23.2M26.7M32.3M
Change To Netincome2.2M3.6M4.7M28.3M32.5M34.1M
Free Cash Flow(24.8M)(32.1M)(9.0M)(21.8M)(19.6M)(20.6M)
Other Non Cash Items341K237K48.7M(10.0M)(11.5M)(11.0M)

Equillium Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Equillium's current stock value. Our valuation model uses many indicators to compare Equillium value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Equillium competition to find correlations between indicators driving Equillium's intrinsic value. More Info.
Equillium is rated # 2 in return on equity category among its peers. It also is rated # 2 in return on asset category among its peers . At this time, Equillium's Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Equillium by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Equillium Systematic Risk

Equillium's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Equillium volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Equillium correlated with the market. If Beta is less than 0 Equillium generally moves in the opposite direction as compared to the market. If Equillium Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Equillium is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Equillium is generally in the same direction as the market. If Beta > 1 Equillium moves generally in the same direction as, but more than the movement of the benchmark.

Equillium Thematic Clasifications

Equillium is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
Pharmaceutical ProductsView
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in Equillium Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Equillium's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Equillium growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.0234

At this time, Equillium's Price Earnings To Growth Ratio is relatively stable compared to the past year.

Equillium March 17, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Equillium help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Equillium. We use our internally-developed statistical techniques to arrive at the intrinsic value of Equillium based on widely used predictive technical indicators. In general, we focus on analyzing Equillium Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Equillium's daily price indicators and compare them against related drivers.

Additional Tools for Equillium Stock Analysis

When running Equillium's price analysis, check to measure Equillium's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Equillium is operating at the current time. Most of Equillium's value examination focuses on studying past and present price action to predict the probability of Equillium's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Equillium's price. Additionally, you may evaluate how the addition of Equillium to your portfolios can decrease your overall portfolio volatility.